Daewoong's Envlo is the new kid on the block for type-2 diabetes treatment – KBR
Daewoong Pharmaceutical said on Thursday Envlo (ingredient: enavogliflozin), a new diabetes drug that inhibits sodium-glucose cotransporter 2 (SGLT-2), obtained domestic approval as monotherapy, metformin combination therapy, and metformin and gemigliptin combination…